Reyataz Labeling Update Cautions Against Use With PPIs
This article was originally published in The Pink Sheet Daily
Executive Summary
Bristol-Myers Squibb’s protease inhibitor adds a study showing Prilosec substantially reduced plasma concentrations.
You may also be interested in...
Lexiva’s Updated Label Allows Concomitant PPI Treatment
GSK/Vertex’s post-marketing study found that proton pump inhibitor use does not lessen the protease inhibitor’s efficacy.
‘Shadow’ Factory Challenges Continue For US FDA
Agency wants more information about API suppliers as it winds up case against KV Tech for hidden use of Dr. Reddy’s plant and seeks to find disappearing manufacturer of contaminated OTC eye drops.
US FDA, USP Raise Questions About Valisure’s Assertions Of Benzoyl Peroxide’s Benzene Risks
The US drug regulatory authority and standard-setting organization are evaluating the drug-screening venture’s findings regarding stability and potential carcinogenic risks associated with the widely used acne treatment, which includes Rx formulations.